Breast Cancer Negligence Claims: Dr Vasileios Angelis Shares His Medico-Legal Expertise

Ardent Expert Chambers Member Dr Vasileios Angelis, Consultant Medical Oncologist, delivered a specialist webinar examining how oncological evidence is applied in breast cancer negligence claims, particularly where the central questions concern delayed diagnosis, treatment decisions and whether an alternative clinical pathway would have materially altered the outcome.

Drawing on his specialist oncology experience, Dr Angelis explored how tumour biology, disease progression and treatment response influence the assessment of causation and prognosis.

The session also examined one of the most difficult areas of oncology expert evidence: determining whether an earlier diagnosis or different treatment would probably have changed the options available to the patient or their longer-term outcome.

Understanding the Biology of Breast Cancer

Breast cancer is not a single disease with a predictable pattern of progression.

Tumours can differ considerably in their biological characteristics, growth rate, response to treatment and potential to recur or spread.

Dr Angelis highlighted why these differences are fundamental when reviewing a case retrospectively.

An expert cannot assume that a particular period of diagnostic delay will have had the same effect in every patient. The likely consequences must instead be considered in the context of the individual cancer, its biological behaviour and the evidence available about its progression.

This disease-specific approach is essential when forming a reliable opinion on causation.

Earlier Diagnosis and Disease Progression

Cases involving delayed breast cancer diagnosis often raise the question of what the disease would probably have looked like had it been identified at an earlier point.

That assessment may require consideration of tumour size, nodal involvement, metastatic spread and the likely stage of disease at different points in the clinical chronology.

Dr Angelis explored how oncologists use the available evidence to reconstruct this potential earlier picture while recognising the limits of retrospective analysis.

The fact that a cancer was diagnosed at a later stage does not automatically establish what its exact stage would have been weeks or months previously.

An expert opinion therefore needs to distinguish between conclusions that can reasonably be supported and areas where biological uncertainty remains.

Assessing Treatment Response

Treatment response formed another important part of Dr Angelis’ webinar.

Breast cancer management may involve combinations of systemic therapy, surgery, radiotherapy and targeted or hormone-based treatment, depending on the characteristics and stage of the disease.

An expert reviewing the case may need to consider how the cancer responded to treatment and what that response reveals about its underlying biology.

Dr Angelis demonstrated why treatment cannot be assessed in isolation from the wider disease course.

Response, resistance, recurrence and progression may all provide important information when considering both the patient's actual clinical pathway and any proposed alternative scenario.

Would Earlier Intervention Have Changed Treatment?

One of the central medico-legal questions in delayed diagnosis cases is whether earlier intervention would actually have altered the treatment available.

A delay may be identifiable without necessarily changing the type of therapy that would have been recommended.

In other cases, earlier diagnosis may potentially have influenced the extent of surgery, the systemic treatment required or the overall therapeutic pathway.

Dr Angelis explored the importance of examining these questions individually rather than assuming that earlier diagnosis automatically means substantially different treatment.

The expert must consider what would probably have been clinically appropriate at the relevant earlier point and how the patient's disease characteristics would have influenced that decision.

Examining ‘Loss of Chance’ Arguments

Dr Angelis also addressed the complex reasoning that can arise where it is argued that delayed diagnosis reduced the patient's prospects of a better outcome.

These cases require careful construction of the counterfactual pathway: what would probably have happened had diagnosis or treatment occurred earlier.

That analysis may involve considering likely disease stage, treatment options, expected response and prognosis at the alternative point in time.

Dr Angelis highlighted the importance of grounding these opinions in clinical evidence rather than assuming that any delay necessarily translated into a measurable change in outcome.

This is particularly important where the difference between the actual and hypothetical clinical pathways is relatively narrow.

Recurrence Risk and Prognosis

Prognosis in breast cancer can depend on numerous factors, including tumour characteristics, disease stage, treatment response and subsequent recurrence.

Dr Angelis explored how these factors may be brought together when providing an expert opinion on longer-term outcome.

Where recurrence has occurred, an expert may need to consider whether it reflects the underlying biology of the cancer or whether there is evidence that an earlier intervention would probably have changed that risk.

Where recurrence has not occurred, questions may still arise regarding future prognosis and how the patient's risk profile has been affected by the clinical pathway.

This requires a nuanced approach rather than reducing prognosis to a single statistic.

Separating Breach From Oncology Causation

A recurring theme throughout the session was the distinction between identifying a problem in the diagnostic pathway and establishing what difference it made from an oncological perspective.

Questions about whether imaging should have been performed, a referral should have occurred or abnormal findings should have been acted upon may sit alongside a separate oncology question: what would have happened to the cancer if that alternative action had taken place?

Dr Angelis’ role as an oncology expert is to address that latter issue through consideration of tumour biology, treatment and prognosis.

Keeping those questions distinct helps ensure that expert evidence remains within the appropriate professional boundaries.

Specialist Expertise in Breast Cancer Medico-Legal Evidence

As a Consultant Medical Oncologist, Dr Angelis brings specialist knowledge of cancer biology, systemic treatment, disease progression and prognosis to his medico-legal practice.

His webinar demonstrated how that expertise is applied when examining complex breast cancer cases involving delayed diagnosis, disputed treatment decisions, recurrence risk, counterfactual treatment pathways and causation.

Rather than assuming that an earlier diagnosis would necessarily have produced a different outcome, his approach considers the individual cancer, the treatments realistically available and the clinical evidence supporting each stage of the analysis.

Dr Vasileios Angelis is a member of Ardent Expert Chambers. View his full member profile to learn more about his specialist expertise and medico-legal practice.

Watch Dr Vasileios Angelis’ webinar, Breast Cancer Negligence Claims >